RGA Stock Analysis: Reinsurance of America | NYSE
Insurance - Reinsurance | NYSE, USA | Market Cap: 16.716m USD | 12M Return: 44.3% | US7593516047 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 111M
EPS Trend: 76.9%
Qual. Beats: 3
Rev. Trend: 92.7%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Reinsurance Group of America (RGA) is a global reinsurer founded in 1973 and headquartered in Chesterfield, Missouri. The company operates across the United States, Latin America, Canada, Europe, the Middle East, Africa, Asia, and Australia, providing reinsurance products to primary insurance companies rather than directly to consumers.
RGAs business is organized around two main segments: life and health reinsurance, and asset-intensive (financial) reinsurance. The life and health segment covers individual and group life, disability, long-term care, and critical illness products, while the financial solutions segment includes longevity reinsurance, stable value products, pension risk transfer transactions, capital solutions, coinsurance of payout annuities, and funding agreement-backed note programs.
As a large-cap Financials sector company listed on the NYSE, RGA assumes mortality, morbidity, lapse, and investment-related risks from its clients. Reinsurers like RGA help primary insurers manage exposure, stabilize earnings, and free up capital, serving as intermediaries that pool and diversify risk across the global insurance industry.
- Higher interest rates boost investment income and asset-intensive margins
- Pension risk transfer and longevity deals drive premium growth
- Capital returns accelerate with buybacks and dividend hikes
| Net Income: 1.51b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: 28.02% < 20% (prev 44.42%; Δ -16.41% < -1%) |
| CFO/TA 0.03 > 3% & CFO 5.20b > Net Income 1.51b |
| Net Debt (43.0m) to EBITDA (2.31b): 0.02 < 3 |
| Current Ratio: 3.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (66.7m) vs 12m ago 0.0% < -2% |
| Gross Margin: 25.18% > 18% (prev 12.43%; Δ 12.75% > 0.5%) |
| Asset Turnover: 17.08% > 50% (prev 16.22%; Δ 0.86% > 0%) |
| Interest Coverage Ratio: 5.74 > 6 (EBIT TTM 2.27b / Interest Expense TTM 396.0m) |
| A: 0.04 (Total Current Assets 10.4b - Total Current Liabilities 3.21b) / Total Assets 167b |
| B: 0.06 (Retained Earnings 10.8b / Total Assets 167b) |
| C: 0.02 (EBIT TTM 2.27b / Avg Total Assets 150b) |
| D: 0.09 (Book Value of Equity 13.7b / Total Liabilities 153b) |
| Altman-Z'' = 0.69 = B |
| DSRI: 0.95 (Receivables 4.74b/4.20b, Revenue 25.7b/21.6b) |
| GMI: 0.49 (GM 12.43% / 25.18%) |
| AQI: 1.01 (AQ_t 0.93 / AQ_t-1 0.92) |
| SGI: 1.19 (Revenue 25.7b / 21.6b) |
| TATA: -0.02 (NI 1.51b - CFO 5.20b) / TA 167b) |
| Beneish M = -3.39 (Cap -4..+1) = AA |
As of October 17, 2026, the stock is trading at USD 266.75 with a total of 441,474 shares traded. Over the past week, the price has changed by +4.21%, over one month by +7.52%, over three months by +11.63% and over the past year by +44.33%.
Current recommended Stop Loss: 259.50 (which is 2.7% or 1.4 ATR below the current price).
Reinsurance of America has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy RGA.
- StrongBuy: 3
- Buy: 4
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 277.6 | 4.1% |
P/E Trailing = 11.2717
P/E Forward = 7.716
P/S = 0.6437
P/B = 1.1767
P/EG = 1.1437
Revenue TTM = 25.7b USD
EBIT TTM = 2.27b USD
EBITDA TTM = 2.31b USD
Long Term Debt = 5.71b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 5.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 43.0m USD (calculated: Debt 5.71b - CCE 5.67b)
Enterprise Value = 16.8b USD (16.7b + Debt 5.71b - CCE 5.67b)
Interest Coverage Ratio = 5.74 (Ebit TTM 2.27b / Interest Expense TTM 396.0m)
EV/FCF = 3.22x (Enterprise Value 16.8b / FCF TTM 5.20b)
FCF Yield = 31.02% (FCF TTM 5.20b / Enterprise Value 16.8b)
FCF Margin = 20.25% (FCF TTM 5.20b / Revenue TTM 25.7b)
Net Margin = 5.87% (Net Income TTM 1.51b / Revenue TTM 25.7b)
Gross Margin = 25.18% ((Revenue TTM 25.7b - Cost of Revenue TTM 19.2b) / Revenue TTM)
Gross Margin QoQ = 32.83% (prev 28.61%)
Tobins Q-Ratio = 0.10 (Enterprise Value 16.8b / Total Assets 167b)
Interest Expense / Debt = 6.94% (Interest Expense 396.0m / Debt 5.71b)
Taxrate = 19.24% (361.0m / 1.88b)
NOPAT = 1.83b (EBIT 2.27b * (1 - 19.24%))
Current Ratio = 3.24 (Total Current Assets 10.4b / Total Current Liabilities 3.21b)
Debt / Equity = 0.42 (Debt 5.71b / totalStockholderEquity, last quarter 13.7b)
Debt / EBITDA = 0.02 (Net Debt 43.0m / EBITDA 2.31b)
Debt / FCF = 0.01 (Net Debt 43.0m / FCF TTM 5.20b)
Total Stockholder Equity = 13.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.00% (Net Income 1.51b / Total Assets 167b)
RoE = 11.29% (Net Income TTM 1.51b / Total Stockholder Equity 13.4b)
RoCE = 11.92% (EBIT 2.27b / Capital Employed (Equity 13.4b + L.T.Debt 5.71b))
RoIC = 1.13% (NOPAT 1.83b / Invested Capital 163b)
WACC = 6.98% (E(16.7b)/V(22.4b) * Re(7.45%) + D(5.71b)/V(22.4b) * Rd(6.94%) * (1-Tc(0.19)))
Discount Rate = 7.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 5.54 | Cagr: 0.11%
[DCF] Terminal Value 76.17% ; FCFF base≈5.09b ; Y1≈5.35b ; Y5≈6.22b
[DCF] Fair Price = 1.47k (EV 95.8b - Net Debt 43.0m = Equity 95.8b / Shares 65.3m; r=8.35% [WACC [floored]]; 5y FCF grow 5.76% → 2.50% )
EPS Correlation: 76.87 | EPS CAGR: 9.89% | SUE: 2.35 | # QB: 3
Revenue Correlation: 92.65 | Revenue CAGR: 11.45% | SUE: -0.08 | # QB: 0
EPS current Quarter (2026-09-30): EPS=6.92 | Chg30d=+0.59% | Revisions=+25% | Analysts=10
EPS current Year (2026-12-31): EPS=29.81 | Chg30d=+0.10% | Revisions=+67% | GrowthEPS=+31.2% | GrowthRev=+14.0%
EPS next Year (2027-12-31): EPS=29.87 | Chg30d=+0.63% | Revisions=+70% | GrowthEPS=+0.2% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: +82% (up=14, down=0)